Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells

US10106620B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• JANSSEN BIOTECH, INC. · US

Inventors

• Richard W. Childs · Bethesda, US
• Maria Berg · Bethesda, US
• Luis Espinoza Calderon · Bethesda, US
• Kate Sasser · Spring House, US
• Ricardo Attar · Lawrenceville, US

Key dates

• Filing date: Jun 15, 2015
• Grant date: Oct 23, 2018
• Expiry date: Oct 16, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/732
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab′)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab′)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.